Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8881644 | 0.82 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL502 | 0.82 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL95370 | 0.82 | TSHR (0.54) | TSHRIDO1AGXTNAAAALDH1A1 | |
| SCHEMBL7617607 | 0.80 | TSHR (0.50) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL5535645 | 0.80 | CA1 (0.43) | TSHRIDO1ALDH1A1CA1CA2 | |
| SCHEMBL223907 | 0.79 | TSHR (0.78) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL97586 | 0.79 | TSHR (0.50) | TSHRNAAAALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL97849 | 0.79 | TSHR (0.50) | TSHRNAAAALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL27597789 | 0.78 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL5535137 | 0.77 | IDO1 (0.48) | IDO1SMN1; SMN2MAPK1L3MBTL1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20100036120-A1 | NOVEL METHOD FOR SYNTHESIS OF 1,4-MORPHOLINE-2,5-DIONES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1517881-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | Syngenta Participations AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-6677473-B1 | TREATMENT, PREVENTION OR AMELIORATION OF ONE OR MORE SYMPTOMS OF THROMBOTIC DISORDERS, UNSTABLE ANGINA OR CANCER | CORVAS INTERNATIONAL INC | 2004-01-13 | — | — | US | disclosed |
| WO-2004002943-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-01-08 | — | — | WO | disclosed |
| US-6333441-B1 | FORMING MIXTURE COMPRISING FORMIC ACID, TRIETHYLAMINE, TRIBUTYLPHOSPHINE, AND TRIS(DIBENZYLIDENEACETONE) DIPALLADIUM (0)-CHLOROFORM ADDUCT IN SOLVENT, ADDING THERETO ALKYNE UNDER EFFECTIVE REDUCTION CONDITIONS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| WO-2001036351-A2 | PLASMINOGEN ACTIVATOR INHIBITOR ANTAGONISTS RELATED APPLICATIONS | CORVAS INTERNATIONAL, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| CN-1265661-A | N-acylamino acid amide compounds and intermediates for preparation thereof | UBE INDUSTRIES (JP) | 2000-09-06 | — | — | CN | disclosed |
| CN-1227548-A | Substituted p-trifluoromethylphenyluracils | BAYER AG (DE) | 1999-09-01 | — | — | CN | disclosed |
| EP-0560532-B1 | Preparation of cis-olefins | NISSAN CHEMICAL IND LTD (JP) | 1999-08-04 | — | — | EP | disclosed |
| EP-0560532-A1 | Preparation of cis-olefins | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-4247548-A | 7α-Methoxycephalosporin derivatives and their pharmaceutical compositions having antibacterial activity | SANKYO COMPANY LIMITED (JP) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | TSHR 3439/4885IDO1 2039/4885AGXT 3693/4885 |
| US-20100036120-A1 | NOVEL METHOD FOR SYNTHESIS OF 1,4-MORPHOLINE-2,5-DIONES | CBR1, CBR3, NOX4 | TSHR 1503/4885IDO1 943/4885AGXT 2807/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | TSHR 110/4885IDO1 2948/4885AGXT 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.